The latest price target for Bio-Path Hldgs (NASDAQ:BPTH) was reported by Roth MKM on July 8, 2024. The analyst firm set a price target for $20.00 expecting BPTH to rise to within 12 months (a possible 1962.07% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Bio-Path Hldgs (NASDAQ:BPTH) was provided by Roth MKM, and Bio-Path Hldgs reiterated their buy rating.

There is no last upgrade for Bio-Path Hldgs

There is no last downgrade for Bio-Path Hldgs.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bio-Path Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bio-Path Hldgs was filed on July 8, 2024 so you should expect the next rating to be made available sometime around July 8, 2025.

While ratings are subjective and will change, the latest Bio-Path Hldgs (BPTH) rating was a reiterated with a price target of $20.00 to $20.00. The current price Bio-Path Hldgs (BPTH) is trading at is $0.97, which is out of the analyst’s predicted range.